Study of Abaloparatide and Bevacizumab in Myelodysplastic SyndromesResearch Question:
What is the safety and tolerability of combined abaloparatide and bevacizumab in patients
with Myelodysplastic Syndromes (MDS)?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The primary objective of this study is to determine the safety and tolerability of
combined abaloparatide and bevacizumab in patients with Myelodysplastic Syndromes
(MDS). A secondary objective is to determine the response to treatment (based on bone
marrow and peripheral blood findings). A tertiary objective is to determine the impact
of therapy on health-related quality of life (HRQOL) and patient-reported outcomes
(PRO). A quaternary (scientific) objective is to determine the impact of treatment
on both hematopoietic and stromal cell populations within the bone marrow of MDS patients.
Study Reference #: UMDS18092
Lead Researcher (Principal Investigator)
Lead Researcher: Jason Mendler
Study Contact InformationStudy Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search